Renin angiotensin system inhibitors and outcome in patients with takotsubo syndrome: A propensity score analysis of the GEIST registry

Here are the Renin angiotensin system inhibitors and outcome in patients with takotsubo syndrome: A propensity score analysis of the GEIST registry journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Renin angiotensin system inhibitors and outcome in patients with cirrhosis, renin angiotensin system inhibitors list, renin angiotensin system inhibitors and outcome in probability, renin angiotensin system inhibitors and enzyme, renin angiotensin system inhibitors and outcome based, renin angiotensin system explained, renin angiotensin system ras inhibitors.

Renin angiotensin system inhibitors and outcome in patients with takotsubo syndrome: A propensity score analysis of the GEIST registry

Background: Few data are available on long-term drug therapy and its potential prognostic impact after Takotsubo syndrome (TTS). Aim of the study is to evaluate clinical characteristics and long-term outcome of TTS patients on Renin Angiotensin system inhibitors (RASi).

Methods: TTS patients were enrolled in the international multicenter GEIST (GErman Italian Spanish Takotsubo) registry. Median follow-up was 31 (Interquartile range 12-56) months. Comparison of RASi treated vs. untreated patients was performed within the overall population and after 1:1 propensity score matching for age, sex, comorbidities, type of trigger and in-hospital complications. Registration: clinicaltrials.gov, NCT04361994, https://clinicaltrials.gov/study/NCT04361994

Results: Of the 2453 TTS patients discharged alive, 1683 (68%) received RASi therapy. Patients with RASi were older (age 71 ± 11 vs 69 ± 13 years, P =.01), with hi gher prevalence of hypertension (74% vs 53%, P <.01) and diabetes (19% v s15%, P =.01), higher admission left ventricular ejection fraction (LVEF) (41 ± 11% vs 39 ± 12%, P <.01) and lower rates of in-hospital complications (18.9% vs 29.6%, P <.01). At multivariable analysis, RASi therapy at discharge was independently associated with lower mortality (HR 0.63, 95% CI 0.45-0.87, P <.01). Survival analysis showed that at long term, patients treated with RASi had lower mortality rates in the overall cohort (log-rank P =.001). However, this benefit was not found among patients treated with RASi in the matched cohort (log-rank P =.168). Potential survival benefit of RASi were present, both in the overall and matched cohort, in 2 subgroups: patients with admission LVEF ≤ 40% (HR 0.54 95% CI 0.38-0.78, P =.001; HR 0.59, 95% CI 0.37-0.95, P =.030) and diabetes (HR 0.41, 95% CI 0.23-0.73, P =.002; HR 0.41, 95% CI 0.21-0.82, P =.011). Conclusions: Long-term therapy with RASi after a TTS ep isode was not associated with lower mortality rates at propensity score analysis. However, potential survival benefit can be found among patients with admission LVEF ≤ 40% or diabetes. © 2024 Elsevier Inc.

Authors : Santoro F.; Stiermaier T.; Núñez Gil I.J.; El-Battrawy I.; Pätz T.; Cacciotti L.; Guerra F.; Novo G.; Musumeci B.; Volpe M.; Mariano E.; Caldarola P.; Montisci R.; Ragnatela I.; Cetera R.; Vazirani R.; Lluch C.; Uribarri A.; Corbi-Pascual M.; Conty Cardona D.A.; Akin I.; Barbato E.; Thiele H.; Brunetti N.D.; Eitel I.; Arcari L.

Source : Elsevier Inc.